multiple sclerosis

Showing 15 posts of 105 posts found.

Teva launches new MS eHealth site

September 4, 2014
Medical Communications, Sales and Marketing Teva, digital, ms ireland, multiple sclerosis, pow health

Teva and MS Ireland have helped launch a new website called Pow Health to give multiple sclerosis patients a “one-stop …

Roche image

Roche to launch new MS collaboration

June 23, 2014
Research and Development, Sales and Marketing MS, Roche, inception sciences, multiple sclerosis, versant ventures

Roche has launched a new research collaboration to investigate ways of reversing the debilitating nerve damage caused by multiple sclerosis …


Genzyme MS drug approved in US

September 13, 2012
Medical Communications Aubagio, Genzyme, Rebif, Sanofi, Tysabri, gilenya, multiple sclerosis

US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …

Genzyme ‘confident’ of FDA nod for MS drug

August 29, 2012
Sales and Marketing Genzyme, Lemtrada, MS, multiple sclerosis

Genzyme insists it is on course to resubmit an existing oncology drug for the treatment of relapsing multiple sclerosis (RMS), …

Tsyabri image

Elan to spin off drug discovery arm

August 14, 2012
Research and Development, Sales and Marketing Elan, Neotype Biosciences, Tysabri, multiple sclerosis

Elan Corporation is to spin off its drug discovery arm Neotype Biosciences to create a separate, quoted company by the …

MS audit finds little improvement in care

October 12, 2011
MS, multiple sclerosis

There has been “little or no improvement” in the care of multiple sclerosis patients over the past five years, according …

Study shows new genetic risk factors for MS

August 15, 2011
Research and Development genes, multiple sclerosis, research and development news

New genetic links to the immune system have been identified as a possible trigger for multiple sclerosis. The exact causes …

Merck KGaA

Merck scraps MS pill cladribine

June 23, 2011
Research and Development, Sales and Marketing Cladribine, Merck KGaA, Movectro, multiple sclerosis

Merck KGaA has pulled all pending applications for its multiple sclerosis pill Movectro and will withdraw it from the markets …

Novartis Gilenya (fingolimod)

Oral MS drug Gilenya launched in the UK

April 19, 2011
Sales and Marketing Novartis, gilenya, multiple sclerosis

Gilenya has become the first oral multiple sclerosis drug to be launched in the UK. Gilenya (fingolimod) is licenced to …

Novartis headquarters

First oral MS pill approved in Europe

March 21, 2011
Sales and Marketing MS, Novaris, fingolimod, first oral multiple sclerosis drug, gilenya, multiple sclerosis

Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …

EMD Serono headquarters

FDA knocks back Merck KGaA’s oral MS drug

March 2, 2011
Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs

US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …

Blog footer

Digital Pharma: Merck Serono sets up MS social network

February 18, 2011
Medical Communications Digital Pharma blog, MS, Merck Serono, Movectro, Rebif, multiple sclerosis, social networking

Merck Serono has set up an international social network for multiple sclerosis patients, saying today’s pharma companies should go beyond …

Merck Serono headquarters

Merck Serono halts Movectro European licence application

February 18, 2011
Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis

Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …

Novartis MS drug steals march over Merck rival

January 24, 2011
Sales and Marketing Cladribine, MS, Merck KGaA, Novartis, fingolimod, gilenya, multiple sclerosis

Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …

Sanofi moves teriflunomide into phase III MS trials

October 26, 2010
Research and Development MS, Sanofi, Sanofi-Aventis, TERACLES, multiple sclerosis, relapsing multiple sclerosis, teriflunomide

Sanofi-Aventis is to begin the first phase III study of an oral drug as an add-on to standard therapy in …

Latest content